Menu
Menu
In this user spotlight, we had the pleasure of interviewing Dr. Robert Akkers, Molecular Biologist at Result Laboratorium, one of our valued and long-standing partners in the Netherlands.
In this thought leadership podcast episode, leading experts from clinical oncology and health technology take a clear-eyed look at where multimodality truly stands today. While widely recognized as the future of oncology, its translation into everyday clinical practice remains uneven and complex.
Explore how the SOPHiA DDM™ variant flagging feature enables you to tap into a global network of expertise, accelerating variant interpretation and increasing confidence in your classifications.
Over many years, Alamut™ Visual Plus has been cited in 1,500 peer-reviewed publications, reflecting its sustained role in variant interpretation across disease areas.
Discover how Dr. Christophe Marzac and his team at Gustave Roussy use the SOPHiA DDM™ Platform to streamline high‑volume genomic workflows, ensure stable variant interpretation, and provide important insights to support hematologic cancer research.
Explore how integrating tissue and liquid biopsies reveals a fuller molecular picture and strengthens precision oncology strategies.
How an NHS England genomics laboratory is streamlining hereditary cancer analysis with SOPHiA DDM™
SOPHiA GENETICS and Myriad Genetics have joined forces to create a unique hybrid CDx model designed for improved efficiency and scalability. Listen to this podcast to explore this groundbreaking partnership.
Discover how precision genomics research at Hospital de Amor, Brazil, uncovered a rare gene fusion in a pediatric glioma, providing valuable insights to support a young patient's health journey.
We spoke with Jason Fenwick at NVIDIA to explore how graphics processing unit (GPU) acceleration is addressing key computational bottlenecks in clinical whole genome sequencing (WGS). The discussion focuses on NVIDIA Parabricks, a GPU-accelerated secondary analysis solution, and its integration into SOPHiA DDM™ for WGS. Jason explains how accelerated alignment and variant calling can significantly reduce analysis time while maintaining the accuracy and reliability required for clinical genomics workflows.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.